111 Capital Invests $904,000 in Bristol Myers Squibb

The fund acquired 20,038 shares of the biopharmaceutical company's stock.

Mar. 3, 2026 at 2:39am

Got story updates? Submit your updates here. ›

111 Capital acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, according to the company's disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,038 shares of the biopharmaceutical company's stock, valued at approximately $904,000.

Why it matters

This investment by 111 Capital in Bristol Myers Squibb reflects the fund's belief in the biopharmaceutical company's growth potential and future prospects. As a major player in the pharmaceutical industry, Bristol Myers Squibb's performance is closely watched by investors and analysts.

The details

111 Capital acquired the 20,038 shares of Bristol Myers Squibb as part of its investment strategy in the 3rd quarter. The shares were valued at around $904,000. Several other institutional investors and hedge funds have also bought and sold shares of the company in recent quarters.

  • 111 Capital acquired the stake in Bristol Myers Squibb in the 3rd quarter.

The players

111 Capital

An investment fund that acquired a new stake in shares of Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This investment by 111 Capital underscores the continued investor interest in Bristol Myers Squibb as a leading player in the pharmaceutical industry. The company's strong pipeline and growth prospects make it an attractive investment target for institutional investors like 111 Capital.